KLAS report: InterSystems TrakCare Tops Global EMR Deployments
The electronic medical record (EMR) technology from InterSystems has been deployed by more hospitals than any other vendor’s software during the past four years, according to a research report published today by the internationally recognized research organization KLAS. InterSystems TrakCare®, a unified healthcare information system, has ‘pulled ahead’ of its competitors as a preferred solution, winning significantly more new hospitals globally (non US) than any other supplier in 2016, the report found.
The influential report examines new hospital EMR contracts worldwide, outside of the United States, and found a significant increase in EMR purchasing decisions across the globe in 2016, with TrakCare being a market leader in new hospital wins. Detailing 56 total hospital wins for InterSystems in 2016, the report acknowledged a lower all-in-cost and high proportion of multi-facility contracts for InterSystems customers.
“Broad functionality and a light IT footprint have led to InterSystems being deployed by more hospitals over the past four years than any other solution,” the report said. “InterSystems’ strong 2016 across Europe, Asia, and the Middle East – which included new contracts with several multihospital organizations in the UK and China – was driven by an all-in cost lower than Cerner’s and Epic’s.”
“InterSystems is working with some of the world’s most digitally progressive healthcare providers, who are using TrakCare to improve care and empower clinicians with clinically advanced IT solutions,” said Christine Chapman, vice president for TrakCare at InterSystems. “The success speaks to our commitment to patients and providers alike, our proven ability to deliver value for customers in diverse countries, and a growing need for solutions that respond to the needs of different care settings.”
Highlights from the report included:
- Hospitals wanting a “good mix of functionality with a lower all-in price” during the past three to four years “deployed or chose to deploy InterSystems more than any other vendor.”
- InterSystems contracts represented the highest total number of inpatient facilities, thanks to decisions by multi-site customers such as a public health board in Scotland, a private maternity group in China, and a private hospital group in England.
- InterSystems was reported to be “winning in the UK,” where healthcare providers were said to prefer InterSystems to UK-specific alternatives, and that despite financing challenges faced in the country, providers finalized several EMR contracts. InterSystems “far and away had the most new hospitals associated to these contracts,” the report said, highlighting signings with a health board in Scotland, a large private hospital group and a consortium of NHS trusts.
- InterSystems is the only vendor featured in the report to have clients in China and Thailand
on their “go-forward solution” with the corporation expanding presence in both countries in 2016 – including a group of maternity hospitals in China and a well-known private hospital in Thailand.
- The report described InterSystems’ expansion in Asia and market presence in Europe and the Middle East, with commentary highlighting new InterSystems contracts in countries including Italy and France and with a hospital group in the United Arab Emirates.
For more information on the KLAS report visit KLAS online at www.klasresearch.com.
About KLAS
KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers to be heard and counted. Working with thousands of healthcare executives and clinicians, KLAS gathers data on software, services, medical equipment and infrastructure systems to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving supplier performance. KLAS was founded in 1996, and their staff and advisory board average 25 years of healthcare information technology experience. Follow KLAS on Twitter at www.twitter.com/KLASresearch.
About InterSystems
InterSystems is the engine behind the world’s most important applications. In healthcare, finance, government, and other sectors where lives and livelihoods are at stake, InterSystems is the power behind what mattersTM. Founded in 1978, InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, visit InterSystems.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170525005796/en/
Contact information
Media Contact:
InterSystems
Tom
Keppeler, +617-551-2116
Tom.Keppeler@intersystems.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iFIT Expands Global Reach with Rollout of AI Coach in 19 Countries2.6.2025 16:00:00 EEST | Press release
iFIT Inc., a global leader in connected fitness and interactive content, today announced the expansion of its iFIT AI Coach (beta) across 19 countries: Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and the UK. This strategic expansion brings iFIT’s intelligent, personalized fitness technology to more athletes around the globe. AI Coach is iFIT’s most advanced digital training tool to date, leveraging proprietary technology and user data to deliver hyper-personalized fitness and wellness plans. The tool adapts dynamically to users' goals, schedules, and performance, offering real-time feedback and motivation across a wide range of fitness categories—from strength and cardio to recovery and mindfulness. “Expanding iFIT AI Coach beyond the U.S. reflects our mission to make intelligent, interactive fitness more accessible around the globe,” said Bart Mueller, Chief I
12BET Makes the Shortlist at the 2025 EGR Marketing & Innovation Awards2.6.2025 15:16:00 EEST | Press release
12BET, a pioneering name in the igaming world since 2007, is honored to be shortlisted in two categories at the 2025 EGR Marketing & Innovation Awards: Sportsbook Marketing Campaign, and Marketing Team of the Year – B2C. This recognition highlights the brand’s ongoing dedication to creating meaningful and original experiences that resonate with sports audiences and digital communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250519535436/en/ The EGR Marketing & Innovation Awards are among the most respected accolades in the online gaming industry. Held annually, the awards celebrate creativity, strategic thinking, and innovation across the sector, attracting participation from many of the world’s leading companies. For 12BET, being named a finalist is a meaningful milestone that showcases the brand’s energy, originality, and deep-rooted passion for sports culture. 12BET’s approach to creativity is rooted in connection
Adtran expands Oscilloquartz atomic clock portfolio with lower-cost optical cesium solutions for wider market adoption2.6.2025 15:00:00 EEST | Press release
Adtran today launched the latest additions to its Oscilloquartz optical cesium portfolio, expanding access to precision timing across a wider range of network environments. The new OSA 3200 SP and OSA 3250 ePRC leverage advanced optical pumping technology, offering improved holdover, simplified maintenance and a typical lifetime of 10 years. Built on the same proven platform as Adtran’s high-end cesium models, the solutions enable telecom operators, data centers, power utilities and defense networks to modernize synchronization infrastructure while lowering operational complexity and cost. The new models also address industry demand for alternatives to legacy magnetic cesium clocks that are more difficult to manage over time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530192819/en/ Adtran’s OSA 3200 SP and OSA 3250 ePRC will bring lower-cost optical pumping cesium technology to new markets and applications. “We develo
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 14:00:00 EEST | Press release
Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expertise across its diverse learner and corporate partner network. Massie continued, “With a network of over 30 manufacturing sites across nine
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 14:00:00 EEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom